Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

SARS-CoV-2 Serologic Assays in Control and Unknown Populations Demonstrate the Necessity of Virus Neutralization Testing

Jennifer A. Rathe, Emily A. Hemann, Julie Eggenberger, Zhaoqi Li, Megan L. Knoll, Caleb Stokes, Tien-Ying Hsiang, Jason Netland, Kennidy Takehara, View ORCID ProfileMarion Pepper, Michael Gale Jr.
doi: https://doi.org/10.1101/2020.08.18.20177196
Jennifer A. Rathe
1Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington
2Department of Pediatric Infectious Disease, Seattle Children’s Hospital / University of Washington
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Emily A. Hemann
1Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julie Eggenberger
1Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhaoqi Li
3Department of Statistics, University of Washington
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Megan L. Knoll
1Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caleb Stokes
1Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington
2Department of Pediatric Infectious Disease, Seattle Children’s Hospital / University of Washington
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tien-Ying Hsiang
1Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jason Netland
1Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kennidy Takehara
1Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marion Pepper
1Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Marion Pepper
Michael Gale Jr.
1Center for Innate Immunity and Immune Disease, Department of Immunology, University of Washington
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mgale{at}uw.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Background To determine how serologic antibody testing outcome links with virus neutralization of SARS-CoV-2 to ascertain immune protection status, we evaluated a unique set of individuals for SARS-CoV-2 antibody detection and viral neutralization.

Methods Herein, we compare several analytic platforms with 15 positive and 30 negative SARS-CoV-2 infected controls followed by viral neutralization assessment. We then applied these platforms in a clinically relevant population: 114 individuals with unknown histories of SARS-CoV-2 infection.

Results In control populations, the best performing antibody detection assays were SARS-CoV-2 receptor binding domain (RBD) IgG (specificity 87%, sensitivity 100%, PPV 100%, NPV 93%), spike IgG3 (specificity 93%, sensitivity 97%, PPV 93%, NPV 97%), and nucleocapsid (NP) protein IgG (specificity 93%, sensitivity 97%, PPV 93%, NPV 97%). Neutralization of positive and negative control sera showed 100% agreement. 20 unknown individuals had detectable SARS-CoV-2 antibodies with 16 demonstrating virus neutralization. The antibody assays that best predicted virus neutralization were RBD IgG (misidentified 2), spike IgG3 (misidentified 1), and NP IgG (misidentified 2).

Conclusion These data suggest that meaningful evaluation of antibody assay performance requires testing in an unknown population. Further, these results indicate coupling of virus neutralization analysis to a positive antibody test is required to categorize patients based on SARS-CoV-2 immune protection status following virus exposure or vaccine administration. One of the antibody detection platforms identified in this study followed by the pseudoneutralization or focus reduction assay would provide a practical testing strategy to assess for SARS-CoV-2 antibodies with optimal prediction of correlates to neutralizing immunity.

Funding Supported by NIH grants AI148684, AI151698, AI145296, and UW funds to the Center for Innate Immunity and Immune Disease.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

Supported by NIH grants AI148684, AI151698, AI145296, and UW funds to the Center for Innate Immunity and Immune Disease.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Approved by UW IRB: Study 00009810

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • The authors have declared that no conflict of interest exists.

Data Availability

All data that is not included in the manuscript and supplemental material is available upon request to interested parties. Data will not be released if it violates the privacy of our subjects as required by our IRB.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted August 21, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
SARS-CoV-2 Serologic Assays in Control and Unknown Populations Demonstrate the Necessity of Virus Neutralization Testing
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
SARS-CoV-2 Serologic Assays in Control and Unknown Populations Demonstrate the Necessity of Virus Neutralization Testing
Jennifer A. Rathe, Emily A. Hemann, Julie Eggenberger, Zhaoqi Li, Megan L. Knoll, Caleb Stokes, Tien-Ying Hsiang, Jason Netland, Kennidy Takehara, Marion Pepper, Michael Gale Jr.
medRxiv 2020.08.18.20177196; doi: https://doi.org/10.1101/2020.08.18.20177196
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
SARS-CoV-2 Serologic Assays in Control and Unknown Populations Demonstrate the Necessity of Virus Neutralization Testing
Jennifer A. Rathe, Emily A. Hemann, Julie Eggenberger, Zhaoqi Li, Megan L. Knoll, Caleb Stokes, Tien-Ying Hsiang, Jason Netland, Kennidy Takehara, Marion Pepper, Michael Gale Jr.
medRxiv 2020.08.18.20177196; doi: https://doi.org/10.1101/2020.08.18.20177196

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (430)
  • Allergy and Immunology (756)
  • Anesthesia (221)
  • Cardiovascular Medicine (3294)
  • Dentistry and Oral Medicine (364)
  • Dermatology (279)
  • Emergency Medicine (479)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1171)
  • Epidemiology (13376)
  • Forensic Medicine (19)
  • Gastroenterology (899)
  • Genetic and Genomic Medicine (5153)
  • Geriatric Medicine (482)
  • Health Economics (783)
  • Health Informatics (3268)
  • Health Policy (1140)
  • Health Systems and Quality Improvement (1190)
  • Hematology (431)
  • HIV/AIDS (1017)
  • Infectious Diseases (except HIV/AIDS) (14629)
  • Intensive Care and Critical Care Medicine (913)
  • Medical Education (477)
  • Medical Ethics (127)
  • Nephrology (523)
  • Neurology (4925)
  • Nursing (262)
  • Nutrition (730)
  • Obstetrics and Gynecology (883)
  • Occupational and Environmental Health (795)
  • Oncology (2524)
  • Ophthalmology (724)
  • Orthopedics (281)
  • Otolaryngology (347)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (543)
  • Pediatrics (1302)
  • Pharmacology and Therapeutics (550)
  • Primary Care Research (557)
  • Psychiatry and Clinical Psychology (4212)
  • Public and Global Health (7504)
  • Radiology and Imaging (1706)
  • Rehabilitation Medicine and Physical Therapy (1013)
  • Respiratory Medicine (980)
  • Rheumatology (480)
  • Sexual and Reproductive Health (497)
  • Sports Medicine (424)
  • Surgery (548)
  • Toxicology (72)
  • Transplantation (236)
  • Urology (205)